Page last updated: 2024-11-06

4-nitrophenyl alpha-glucoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitrophenyl alpha-glucoside: RN given refers to (alpha)-anomer; see also (beta)-anomers: 29857-05-4, 2492-87-7; cpd with unspecified anomer: 5779-46-4 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-nitrophenyl alpha-D-glucoside : An alpha-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92969
CHEMBL ID1235365
CHEBI ID91122
SCHEMBL ID60405
MeSH IDM0072001

Synonyms (44)

Synonym
pnpalphaglu
4-nitrophenyl |a-d-glucopyranoside
CHEMBL1235365
3767-28-0
4'-nitrophenyl-alpha-d-glucopyranoside
PNG ,
4-nitrophenyl alpha-d-glucopyranoside, >=99%
p-nitrophenyl-alpha-d-glucopyranoside
p-npg
bdbm23837
p-nitrophenyl alpha-d-glucopyranoside
(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
4-nitrophenyl alpha-glucoside
4-nitrophenyl alpha-d-glucopyranoside
4-nitrophenyl-alpha-d-glucopyranoside
N0493
AKOS015919382
p-nitrophenyl-glucopyranoside
einecs 223-189-3
AKOS016015693
SCHEMBL60405
N-4351
4-nitrophenyl-alpha-d-glucopyranoside, beta-anomer < 0.1%
4-nitrophenyl alpha-d-glucoside
CHEBI:91122
p-nitrophenyl alpha-d-glucoside
4-nitrophenyl a-d-glucopyranoside
4-nitrophenyl-i+/--d-glucopyranoside
IFBHRQDFSNCLOZ-ZIQFBCGOSA-N
Q27163063
a-d-glucopyranoside, 4-nitrophenyl
A12469
(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-(4-nitrophenoxy)tetrahydro-2h-pyran-3,4,5-triol
AMY41438
A874035
p-nitrophenyl-alpha-d-glucoside
4-nitrophenyl- alpha -d- glucopyranoside
pnp-alpha-d-glc
BS-42446
HY-W011411
wurcs=2.0/1,1,0/[a2122h-1a_1-5_1*o(c^ec^zc^ec^ec^zc^e$3)/6no/9=o]/1/
CS-W012127
PD165975
DTXSID701031992

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Active absorption in the intestine and metabolism of the beta- and alpha-anomers of the glucoside and galactoside of p-nitrophenol (p-NP) were studied to find a more suitable prodrug for poorly absorbed drugs."( Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
alpha-D-glucoside
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID590727Activity at Bacillus stearothermophilus alpha-glucosidase assessed as production of chromogenic p-Nitrphenol measured after 3 mins by HPLC and Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties.
AID590730Ratio of Kcat to Km for Bacillus stearothermophilus alpha-glucosidase assessed as production of chromogenic p-Nitrphenol2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties.
AID222170Binding affinity against melibiose permease of Escherichia coli2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Syntheses and properties of photoactivatable sugar derivatives designed to probe the sugar-binding site of melibiose permease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (19.64)18.7374
1990's10 (17.86)18.2507
2000's15 (26.79)29.6817
2010's19 (33.93)24.3611
2020's1 (1.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.55 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (98.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]